Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps

Santomasi, Carla; Buonamico, Enrico; Dragonieri, Silvano; Lulaj, E; Maselli, Leonardo; Iorillo, Ilaria; Piccinno, S; Capuano, A; Ahroud, M; Lazzaretti, I Dei; Iannuzzi, Lucia; Carpagnano, Giovanna Elisiana

doi:10.1183/13993003.congress-2022.575

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, a number of patients presented an important in polyp burden [37]. The same results were obtained in Italy [38][39][40][41].…”

Section: Anti-il5supporting

confidence: 67%

Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy

Cergan,

Berghi,

Dumitru

et al. 2023

Life

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is an important ENT pathology which affects about 5–12% of the general population. The treatment of CRS can be pharmacological (nasal sprays, douches, systemic antibiotics and steroids), surgical (endoscopic sinus surgery) or immunological according to established algorithms. CRS was divided for many years into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). New ways of classifying CRS by endotypes (presence of neutrophilia, eosinophilia, fibrosis, glandular hypertrophy and epithelial dysmorphisms) appeared after the most recent understandings of the pathophysiology of the disease. Other classifications divide CRS into primary and secondary forms, localized/diffuse types and anatomical presentation. A new type of treatment has been administered in the last years, biologics. For the moment, biologics are indicated just in the cases of the patients who have undergone ESS or have contraindications for surgery and have bilateral polyps and meet a minimum of three of the following criteria: the necessity for systemic therapies with oral or parenteral corticosteroids or contraindications to systemic steroids, significant loss of smell or impaired QoL score, comorbid asthma and type 2 inflammation. This article aims to present the most relevant studies which used the three types of biologics (anti-IgE, anti-IL5 and anti-IL4/IL3) and wishes to increase the awareness of this new type of treatment that can be used in some CRS cases.

show abstract

“…Also, a number of patients presented an important in polyp burden [37]. The same results were obtained in Italy [38][39][40][41].…”

Section: Anti-il5supporting

confidence: 67%

Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy

Cergan,

Berghi,

Dumitru

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…Benralizumab not only induced profound beneficial effects in term of asthma symptoms but also improved sinonasal symptoms in comorbid patients with CRSwNP, as demonstrated by the significant and progressive changes recorded in VAS and SNOT Although benralizumab currently lacks the indication for the treatment of CRSwNP, growing evidence indicates that the anti IL-5R has a positive impact on nasal symptoms in comorbid patients [38][39][40][41]. Notably, a recent work by Santomasi and colleagues showed that benralizumab was not only effective in decreasing SNOT 22 score, but it also significantly reduced nasal polyps score (NPS), determined by nasal endoscopy, and the number of nasal eosinophils and neutrophils, assessed via nasal cytology, in SEA patients with CRSwNP [41]. Collectively, these data corroborate the theory of "united airway disease" [42], implying that SEA and CRSwNP share the same eosinophilic-driven pathophysiology in comorbid patients, and benralizumab could indeed represent the optimal therapeutic strategy to tackle both pathologies simultaneously.…”

Section: Discussionmentioning

confidence: 98%

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

Pini,

Bagnasco,

Beghe

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Severe eosinophilic asthma (SEA) represents a substantial global health burden. Benralizumab has been shown to restore good control of asthma. Robust data on benralizumab effectiveness over periods longer than 2 years are still scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Clinical outcomes were evaluated at 6, 12, 24 and 36 months. Partial and complete clinical remission (CR) were also assessed. Data were analysed either with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: Benralizumab induced a persistent reduction in exacerbation rates (p

show abstract

“…Benralizumab not only induced profound beneficial effects in terms of asthma symptoms but also improved sinonasal symptoms in comorbid patients with CRSwNP, as demonstrated by the significant and progressive changes recorded in VAS and SNOT-22. Although benralizumab currently lacks the indication for the treatment of CRSwNP, growing evidence indicates that the anti-IL-5R has a positive impact on nasal symptoms in comorbid patients [42][43][44][45]. Notably, a recent work by Santomasi and colleagues showed that benralizumab was not only effective in decreasing the SNOT-22 score, but it also significantly reduced the nasal polyps score (NPS), determined by nasal endoscopy, and the number of nasal eosinophils and neutrophils, assessed via nasal cytology, in SEA patients with CRSwNP [45].…”

Section: Discussionmentioning

confidence: 99%

“…Although benralizumab currently lacks the indication for the treatment of CRSwNP, growing evidence indicates that the anti-IL-5R has a positive impact on nasal symptoms in comorbid patients [42][43][44][45]. Notably, a recent work by Santomasi and colleagues showed that benralizumab was not only effective in decreasing the SNOT-22 score, but it also significantly reduced the nasal polyps score (NPS), determined by nasal endoscopy, and the number of nasal eosinophils and neutrophils, assessed via nasal cytology, in SEA patients with CRSwNP [45]. Collectively, these data corroborate the theory of "united airway disease" [46], implying that SEA and CRSwNP share the same eosinophilic-driven pathophysiology in comorbid patients, and benralizumab could indeed represent the optimal therapeutic strategy to tackle both pathologies simultaneously.…”

Section: Discussionmentioning

confidence: 99%

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

Pini,

Bagnasco,

Beghè

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Partial and complete clinical remission (CR) were assessed. Data were analyzed with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: At 36 months, benralizumab reduced the exacerbation rate by 89% and increased the forced expiratory volume in 1 second (FEV1) (+440 mL at 36 months, p < 0.0001). Benralizumab improved asthma control as well as sinonasal symptoms in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Up to 93.33% of patients either reduced or discontinued OCS; benralizumab also decreased ICS use and other asthma medications. Overall, 84.31% of patients achieved partial or complete CR. Conclusions: Benralizumab improved asthma and sinonasal outcomes up to 36 months. These findings support the potential of benralizumab to induce CR, emphasizing its role as a disease-modifying anti-asthmatic drug for the management of SEA. Further research is warranted to expand these findings by minimizing data loss and assessing benralizumab’s long-term safety.

show abstract

Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps

Cited by 4 publications

References 0 publications

Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy

Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

Contact Info

Product

Resources

About